The Retiree Whose Loyalty Stock Became a Golden Cage

When a financial planner first charted her asset allocation, the pie chart was almost comically lopsided: one enormous green wedge labeled PharmaCorp, and tiny slivers for everything else. Her 401(k) rollover held $300,000. A savings account contributed $140,000. But the $1.5 million in stock dwarfed everything, representing 72% of her investable net worth.

Concentration risk is one of the most common — and most overlooked — threats facing retirees who spent careers at publicly traded companies. Academic research suggests that a single-stock position exceeding 10-15% introduces uncompensated risk: volatility that the market doesn't reward you for bearing. Elizabeth's position is nearly five times that threshold.

Elizabeth watched PharmaCorp's stock price triple during the 2010s as her oncology division produced two blockbuster drugs. She weathered a 40% drawdown during the pandemic and held firm. That resilience felt like wisdom at the time. In retirement, with no paycheck to replenish losses, the same stubbornness carries a different kind of cost.

Elizabeth's reluctance isn't purely emotional. Her $1.5 million position carries $1.38 million in unrealized gains. At the federal rate of 15% plus the 3.8% NIIT, she'd owe roughly $259,000 to Washington. New Jersey's capital gains tax (up to 10.75%) would add approximately $50,000 more. A full liquidation would cost her north of $300,000 — enough to fund five years of current spending.

This is the textbook concentrated stock dilemma: too large to ignore, too expensive to exit all at once. Financial planners call it being "tax-locked."

The key insight her advisor introduced: diversification doesn't have to happen in a single taxable event. A multi-year harvesting strategy — selling tranches calibrated to stay within favorable tax brackets — can spread the pain across five to seven years. Selling roughly $200,000 annually would generate gains that, combined with her pension and Social Security, keep her in the 15% federal bracket rather than pushing into 20%.

Elizabeth's advisor identified two advanced strategies. First, the roughly $85,000 of PharmaCorp shares still inside her 401(k) qualify for Net Unrealized Appreciation (NUA) treatment. She can distribute those shares in-kind to a taxable brokerage, paying ordinary income tax only on the original cost basis (~$9,000) rather than the full market value. The remaining appreciation gets taxed at long-term capital gains rates only when she sells — and if she holds until death, heirs inherit the step-up.

The second strategy is more transformative. A Charitable Remainder Unitrust (CRUT) would allow Elizabeth to transfer $500,000 of shares into an irrevocable trust. The trust sells with no immediate capital gains tax, reinvests in a diversified portfolio, and pays Elizabeth 5-7% annually for life. At her death, the remainder goes to charity. She receives an immediate income tax deduction plus a diversified income stream.

The catch is irrevocability. Once shares enter the CRUT, she cannot change her mind. For someone whose identity is wrapped up in those shares, signing them away requires a different kind of courage than simply pressing "sell."

While the stock concentration dominates planning conversations, her advisor flagged another vulnerability: no long-term care insurance and no dedicated healthcare plan beyond Medicare. A 65-year-old woman can expect to spend approximately $165,000 on healthcare throughout retirement — excluding long-term care, which can double or triple the total.

Elizabeth's mother lived to 94 and spent her final three years in a memory care facility at $9,500 per month. Elizabeth watched her father's savings evaporate. The experience left her terrified but paradoxically paralyzed.

The healthcare question connects directly to the stock concentration. If Elizabeth needs $300,000 for extended care in her eighties and PharmaCorp has declined 50%, she faces a catastrophic shortfall. Diversifying now isn't just about optimizing returns — it's about ensuring the money is there when her body, not the market, dictates the timeline.

Her advisor assembled a five-year plan to reduce PharmaCorp from 72% to under 25% while minimizing cumulative taxes. Year one: NUA election for 401(k) shares and establishing the CRUT with $500,000. Years two through five: selling $150,000-$200,000 of remaining shares annually, tax-loss harvesting where possible, and reinvesting into index funds, Treasuries, and TIPS for inflation protection.

By the end of the five-year plan, Elizabeth's portfolio would hold roughly $350,000 in PharmaCorp (a manageable 18%), $800,000 in diversified taxable investments, $300,000 in her IRA, and income flowing from the CRUT. Her healthcare reserve would be funded. Her estate plan — including a donor-advised fund seeded with appreciated shares — would be in place. The single ticker that once defined her financial identity would become one piece of a resilient whole.

I spent thirty years building something at PharmaCorp. I'm not abandoning it — I'm graduating from it. The company gave me a career. Now I need a portfolio that gives me a retirement.

— Elizabeth Foster